Search
Autolus Therapeutics PLC
AUTLAdd to Watchlist
1.910USD
-0.040-2.05%
Close 09-24 16:00（ET）
508.37MMarket Cap
LossP/E TTM
Autolus Therapeutics PLC (AUTL) Stock Price Target & Forecast
Analyst Rating
Based on 10 analysts giving stock ratings to Autolus Therapeutics PLC in the past month.
Buy
4 Strong Buy
6 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
8.850USD+353.85%
AUTL Analyst Recommendation Trends
In the current month, AUTL has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AUTL average Analyst price target in the last month is 8.850.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
4
4
4
4
4
4
4
4
6
6
8
8
8
7
7
7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10
10
12
12
12
11
11
11
AUTL Analyst Rating for Peer Comparison
Updated: Sep 24, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Amgen Inc
AMGN
4
12
18
2
1
37
Biogen Inc
BIIB
7
17
12
1
0
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Merck & Co Inc
MRK
8
14
10
0
0
32
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Vertex Pharmaceuticals Inc
VRTX
9
16
5
0
1
31
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Regeneron Pharmaceuticals Inc
REGN
6
14
10
0
0
30
Financial Forecasting
Based on analysts' estimates, AUTL EPS is projected to reach -0.159 in FY2026Q3, following reported EPS of -0.147 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.27
-0.26
-0.22
-0.16
-0.16
Actual
-0.34
-0.27
-0.15
--
--
Surprise
-27.48%
-4.62%
+31.88%
--
--
FAQs
What is Autolus Therapeutics PLC's expected revenue for the next quarter?
Autolus Therapeutics PLC's expected revenue is 39.96M.
What is Autolus Therapeutics PLC's price target?
Analysts forecast that Autolus Therapeutics PLC's price target is USD 8.85, with the highest forecast at USD 11.00 and the lowest forecast at USD 5.80.
How have Autolus Therapeutics PLCAUTL's recent earnings per share performed?
The market expectation was USD -0.15, while Autolus Therapeutics PLCAUTL's earnings per share (EPS) for the previous quarter was USD -0.27. EPS for the next quarter is expected at USD -0.16.
What is the analyst rating for Autolus Therapeutics PLC?
Based on the ratings of Autolus Therapeutics PLC's stock from 10 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.